PMDA drug package insert
サラゾスルファピリジン腸溶錠250mg「CH」（旧製品：処方変更前、使用期限2026年11月まで）
PMDA Prescription drug · 長生堂製薬株式会社 · package insert Nov 10, 2025
Key facts
| Brand names | サラゾスルファピリジン腸溶錠250mg「CH」（旧製品：処方変更前、使用期限2026年11月まで）, サラゾスルファピリジン腸溶錠500mg「CH」 |
|---|---|
| Nonproprietary names | サラゾスルファピリジン |
| Companies | 製造販売元（輸入元）／長生堂製薬株式会社, 販売元／日本ジェネリック株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗リウマチ剤 |
| Therapeutic category codes | 876219 |
| YJ codes | 6219001H2095, 6219001H1102 |
| Approval numbers | 22600AMX00888000, 22600AMX00889000 |
| Package insert edition | 第3版 |
| Package insert date | Nov 10, 2025 |
| PMDA document key | 450064_6219001H1102_2 |
| PMDA company code | 450064 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: